Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges
Arginine Deprivation: Preclinical Data The initial phase I/II studies of ADI-PEG20 were performed in patients with liver cancer and melanoma, tumors with a high frequency of ASS1 loss (Table 1) [33,98-105]. Following the first intramuscular injection of 1...